Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : A197
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Dompe Farmaceutici
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : A197, novel, first-in-class, topical immunomodulatory agent for treatment of dry eye disease. Primary endpoint of trial measures change from baseline in corneal fluorescein staining with key secondary endpoint evaluating eye dryness symptoms using VAS.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 11, 2022
Lead Product(s) : A197
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Dompe Farmaceutici
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : A197
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate the Safety, Tolerability, and Efficacy of A197 in Subjects With Dry Eye Disease
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 14, 2022
Lead Product(s) : A197
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : A197
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Safar Partners
Deal Size : $10.5 million
Deal Type : Series A Financing
Aramis Biosciences Launches to Address Unmet Needs in Ocular Immunology
Details : Proceeds from the financing will be used to advance the company’s pipeline, including its lead product A197, first-in-class, topical immunomodulatory agent licensed from Dompé farmaceutici, through Phase II clinical proof of concept for the treatment ...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 15, 2021
Lead Product(s) : A197
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Safar Partners
Deal Size : $10.5 million
Deal Type : Series A Financing